Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies
An erratum to this article was published (Diabetes Care, 14 Oct 2026 ↗)
Pooled result · MALOsResult — go to the resultHazard ratio 0.83 95% CI 0.72–0.95Authors' conclusion
SGLT2 inhibitor use was associated with lower risk of MALOs for patients with T2DM.
Study context
- Population
- Patients with T2D
- Participants
- 626,104 patients8 cohort studies
- Comparison
- SGLT2i vs other glucose-lowering medications
- SGLT2 inhibitorsn = 397,806
- Other glucose-lowering medicationsn = 228,298reference
- Outcome
- Incidence rate of major adverse liver-related outcomes (MALOs): composite of hepatic decompensation events, hepatocellular carcinoma, liver transplantation or liver-related deaths
- Follow-up
- Median 2.7 years
Methodological detailsactive-comparator, new-user cohort studies, random-effects models
- Active-comparator, new-user cohort studies
- Random-effects models
Pooled result
MALOs
Hazard ratio
0.83
95% CI 0.72–0.95
SGLT2ivs Other glucose-lowering agents
HR 0.83 (95% CI 0.72–0.95)
As reported in the abstract
Further pooled results
| Outcome | HR (CI) | |
|---|---|---|
| Liver-related deaths · median 2.7 yearsSGLT2ivs Other glucose-lowering agentsRandom-effects; I2 = 0% | 0.64 (0.50–0.82) | |
| 0.512Hazard ratio (log scale) |
MALOs by comparator
- Significant MALO risk reduction vs DPP-4i, metformin or pioglitazone but not vs GLP-1 RA
Sensitivity analyses and publication bias
- Sensitivity analyses did not modify results; funnel plot showed no significant publication bias
Original publication
Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies. Diabetes Care. Published 20 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →